VetMedGuide

Vet Med Guide

Diagnostics2026-05-14 · 10 min read

When to Refer a Cancer Patient: FNA, Biopsy, Staging, and the Decisions That Cannot Wait

A primary-care workflow for deciding when to aspirate, when to biopsy, when to stage, and when to refer a dog or cat with a suspected tumor — based on the 2026 AAHA Oncology Guidelines.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Cancer affects roughly 50% of dogs and 30% of cats over the age of 10, according to the 2026 AAHA Oncology Guidelines for Dogs and Cats. Most of these patients present first to a primary care veterinarian. What happens in that first visit — whether a mass is aspirated or watched, whether staging starts before or after referral, whether the owner gets a clear explanation of options — shapes the trajectory of the case.

This article is about the decision sequence: when to pursue FNA (fine needle aspiration), when biopsy is necessary, what staging means in practice, and when referral to a veterinary oncologist is the right next step rather than a last resort. It is written from the primary-care workflow perspective outlined in the 2026 AAHA Oncology Guidelines.

The first rule: get a diagnosis before planning treatment

The AAHA guidelines are blunt on this point: a suspicion or diagnosis of cancer should be the beginning of the diagnostic process, not the end. Too many treatment plans — surgical excision, steroids, "watch and wait" — are initiated based on the look and feel of a mass without a tissue diagnosis.

The guidelines state that a cytologic or histopathologic diagnosis is needed in most cases, and tumor stage and grade are often necessary as well, before prognosis can be assessed and an optimal treatment plan developed.

This is not academic. Mast cell tumors, soft tissue sarcomas, and mammary carcinomas can look nearly identical on the surface but carry vastly different prognoses and require different surgical margins. Treating a grade I mast cell tumor like a grade III — or vice versa — changes outcomes.

FNA: the fastest first step for most masses

Fine needle aspiration is minimally invasive, typically does not require sedation, and can often be performed during the initial examination. A 22–25 gauge needle is inserted into the mass, cells are collected, and slides are submitted to a clinical pathologist.

When FNA is the right starting point

  • Any new, growing, or changing cutaneous or subcutaneous mass.
  • Enlarged peripheral lymph nodes. Particularly if the node is firm, fixed, or progressively enlarging. Lymphoma — one of the most treatable veterinary cancers — is often diagnosed on FNA alone.
  • Mast cell tumors, lipomas, sebaceous cysts, and abscesses typically exfoliate well and yield diagnostic cytology.

When FNA is not enough

FNA collects cells but does not preserve tissue architecture. That means it cannot determine tumor grade — which is critical for mast cell tumors, soft tissue sarcomas, and many other tumor types where grade directly dictates surgical margins, follow-up therapy, and prognosis.

FNA may also be insufficient or misleading for:

  • Fibrous or dense tumors that do not exfoliate well (some sarcomas, some carcinomas).
  • Oral masses. The University of Tennessee veterinary oncology service specifically recommends biopsy over FNA for oral tumors because aspiration is frequently non-diagnostic and the distinction between melanoma, squamous cell carcinoma, and fibrosarcoma changes the entire treatment plan.
  • Bone tumors. Radiographic appearance is suggestive but tissue confirmation is needed before amputation or limb-spare surgery.
  • Masses where the FNA result is non-diagnostic or equivocal. A nondiagnostic aspirate does not mean the mass is benign. It means you need a different sampling method.

Biopsy: when tissue architecture changes the plan

A biopsy — whether incisional (wedge, punch) or excisional (complete removal) — provides the pathologist with tissue structure, not just individual cells. This enables:

  • Tumor typing with higher confidence.
  • Grading (low, intermediate, high) for tumors where grade predicts behavior.
  • Margin assessment if the entire mass is removed.

Critical biopsy principle: plan the tract

If biopsy is performed in primary care and referral for definitive surgery is possible, the biopsy tract must be placed where it can be excised during the definitive surgery. Tumor cells can seed the biopsy tract. If the tract cannot be removed with the definitive resection, the patient's surgical options may be compromised.

The AAHA guidelines emphasize this point: a poorly placed biopsy is not just a missed diagnostic opportunity — it can be a source of tumor spread that limits future treatment.

Staging: what it means and what it costs the patient

Staging determines whether the cancer is local or has spread. The appropriate staging workup depends on the tumor type, not on a generic panel. The AAHA guidelines recommend that staging tests be "selectively performed based on their diagnostic relevance, prognostic value, and compatibility with the pet's needs and the client's priorities and limitations."

Common staging components

Test What it tells you When it is most relevant
3-view thoracic radiographs Lung metastasis Any tumor with metastatic potential (osteosarcoma, hemangiosarcoma, mammary carcinoma, high-grade mast cell tumor, melanoma)
Abdominal ultrasound Visceral metastasis, lymph node involvement Hemangiosarcoma, mast cell tumors (assess spleen, liver, nodes), transitional cell carcinoma
Regional lymph node FNA Nodal metastasis Any tumor with lymphatic spread potential; do not assume a normal-sized node is disease-free
CBC, chemistry, urinalysis Systemic health, paraneoplastic effects, organ function before anesthesia or chemotherapy Baseline for any patient prior to treatment
CT or MRI Surgical planning, radiation planning, thorough metastasis check Tumors in complex anatomical sites (oral, nasal, brain, body wall); preoperative planning for limb-spare procedures

The key insight from the guidelines: staging does not have to be all-or-nothing. A client who cannot afford a full CT and abdominal ultrasound can still benefit from thoracic radiographs and a lymph node aspirate, which may be sufficient to rule out gross metastatic disease for many tumor types.

When to refer: triggers that should not wait

The AAHA guidelines reframe referral as "a proactive strategy" rather than a last resort. The guidelines' key message: referral preserves options. Delaying referral until a mass is massive, until margins are positive, or until the cancer has spread reduces what any oncologist can do.

Specific referral triggers

Refer early when:

  • The mass is in a difficult location — oral cavity, periocular, inguinal, axillary, or involving bone. These locations require advanced surgical planning and often radiation or reconstructive techniques not available in primary care.
  • The tumor type or grade is aggressive. High-grade mast cell tumors, grade III soft tissue sarcomas, oral melanoma, osteosarcoma, and hemangiosarcoma all benefit from early specialist involvement.
  • Staging reveals metastasis or suspected metastasis. Systemic therapy (chemotherapy, immunotherapy, targeted therapy) usually requires oncology oversight.
  • The owner is considering all options. Oncology referrals provide access to clinical trials, radiation therapy, and treatment combinations not available in general practice.
  • FNA or biopsy reveals a tumor type the primary veterinarian does not treat regularly. This is not a reflection on the veterinarian — it is an acknowledgment that cancer therapy is increasingly subspecialized.

You can often manage in primary care when:

  • The tumor is low-grade and in an accessible location.
  • Wide surgical margins are achievable in your practice setting.
  • You have a confirmed histopathologic diagnosis and grade before surgery.
  • A referral relationship is in place for postoperative questions or complications.

The Laverdia factor

With the FDA's full approval of Laverdia (verdinexor tablets) for at-home oral treatment of canine lymphoma, primary care veterinarians have a new option for managing lymphoma cases that previously would have required referral. However, the AAHA guidelines note that even when primary care veterinarians manage treatment, oncologist consultation is valuable for staging, protocol selection, and monitoring. The decision to treat lymphoma in-house should be made with awareness of the full range of options, including multi-agent chemotherapy protocols that still require specialist oversight.

Quality-of-life assessment: not just an end-of-life conversation

The AAHA guidelines include structured quality-of-life assessment as part of the oncology workflow, not something deferred to the final visit. This is because treatment decisions — whether to pursue surgery, whether to start chemotherapy, whether to refer — depend on the dog or cat's current quality of life, not just the tumor's biology.

Practical quality-of-life indicators include:

  • Pain score. Is the tumor causing pain, and is it controllable with analgesics?
  • Appetite and weight. Cancer cachexia and treatment-related nausea affect willingness to continue therapy.
  • Activity and interest. Is the dog still engaged with the household? Is the cat still grooming?
  • Owner assessment. Research consistently shows that owners are reliable judges of their pet's quality of life when given structured questions.

These assessments should happen at every recheck, not just when the owner raises concerns.

Communication: the referral conversation

The AAHA guidelines emphasize structured communication — scripts, frameworks, and team-based approaches — for talking with clients about cancer diagnosis and referral. Key principles:

  • Avoid euphemisms. "Growth," "lump," and "mass" are not substitutes for "tumor" or "cancer" when the diagnosis is known.
  • Explain what referral means. Many owners equate referral with "giving up" or "expensive treatment I can't afford." Referral is a consultation. The oncologist presents options; the owner decides.
  • Normalize second opinions. Present referral as standard practice for complex cases, not as an admission of failure.
  • Involve the whole team. Veterinary technicians, referral coordinators, and client service representatives all play roles in guiding clients through a cancer diagnosis. The guidelines explicitly highlight team optimization.

A practical workflow summary

  1. New mass identified. Perform FNA unless the location or character makes biopsy the more appropriate first step (oral masses, bone lesions).
  2. FNA is diagnostic. If cytology reveals a tumor type, determine grade (if applicable from cytology; may require biopsy) and stage.
  3. FNA is non-diagnostic. Proceed to biopsy. Place the tract so it can be excised with the definitive surgery.
  4. Diagnosis confirmed. Stage based on tumor type. Refer to an oncologist if the tumor is high-grade, in a complex location, or if the owner wants to explore all options.
  5. Treatment decision. Made collaboratively among the primary veterinarian, the specialist (if involved), and the owner. Quality of life is assessed at every step.
  6. Ongoing care. Whether managed in primary care or specialty practice, rechecks include tumor surveillance, quality-of-life assessment, and client communication.

Sources

Topics
Oncology
Related Articles